Biohit Oyj, Press release, December 18, 2017 at 9:30 am local time (EET)
Biohit Oyj and R-kioski Oy have signed an agreement for the distribution of the smoking cessation product, Acetium lozenge in Finland. The contract is a non-exclusive distribution agreement. Launch date for the product will be announced later.
The new Acetium lozenge is an effective and safe product that helps quit smoking without nicotine. Acetium lozenge has no side effects and its efficacy has been confirmed in clinical trials. Acetium lozenge eliminates cigarette smoke-derived carcinogenic acetaldehyde in the saliva during smoking. According to the results of the clinical trial, Acetium lozenge usage helps in smoking cessation (1-3).
Category Manager Harri Saalasti, R-kioski: ”At R-kioski we aim to bring new innovations to the market. We believe that Acetium lozenge will bring something new to the market for nicotine replacement therapy products."
CEO Semi Korpela, Biohit Oyj: "Smoking is the main cause of preventable diseases and premature deaths worldwide. Acetium lozenge is a breakthrough in developing nicotine-free smoking cessation methods. If you want to quit smoking, Acetium lozenge is the primary way since it is not based on maintenance of nicotine dependence and has no side effects."
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Category Manager Harri Saalasti, R-kioski Oy
tel. +358 20 5544 000
harri.saalasti@r-kioski.fi, www.r-kioski.fi
1. Syrjänen K, Eronen K, Hendolin P, Paloheimo L, Eklund C, Bäckström A, Suovaniemi O. Slow-release L-cysteine (Acetium®) lozenge is an effective new method in smoking cessation. A randomized, double-blind, placebo-controlled intervention. Anticancer Res 2017;37:3639-3648.
2. https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=785626&lang=en
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
R-Kioski in brief
R-kioski is a profitable franchise-driven convenience store chain, which by its versatile product range provides customers with entertainment, excitement, pleasure as well as basic everyday products and services quick and convenient from morning to night. R-kioski is a part of Reitan Convenience and Reitan Group, and has a nationwide coverage with approx. 600 stores and a brand recognition of 98%.
Reitan Convenience comprises R-kioski in Finland, Narvesen in Norway and Latvia, Pressbyrån in Sweden, 7-Eleven and Shell/7-Eleven in Norway, Sweden and Denmark, R-kiosk in Estonia and Lietuvos Spauda in Lithuania. Reitan Convenience is the Market Leader in all seven countries. Reitan Convenience had a turnover of EUR 1,76 billion in 2016 and the number of stores was approx. 2 300. Reitan Group’s turnover in 2016 was EUR 9,8 billion with 38 000 co-workers.